胰腺癌中谷氨酰胺代谢重构的研究进展

doi:10.16352/j.issn.1001-6325.2024.11.1613

摘要/Abstract

摘要： 胰腺癌的肿瘤发生过程高度依赖谷氨酰胺(Gln),多个致癌基因及其下游效应器参与了Gln的代谢重构。因此,胰腺癌对Gln的依赖性及其分子机制有望成为未来的治疗靶点。近期关于胰腺癌中Gln代谢重构的研究进展主要集中在对其关键酶的抑制、对化疗耐药的影响以及Gln拮抗剂的运用,为探索新的治疗策略提供了理论基础。

关键词: 谷氨酰胺, 谷氨酰胺代谢, 胰腺癌, 肿瘤代谢, 综合疗法

Abstract: Pancreatic cancer relies on glutamine (Gln) in its carcinogenesis. Gln metabolism is reprogrammed by multiple oncogenes and their downstream effectors in pancreatic cancer cells. The Gln dependence and its underlying molecular mechanisms can potentially be exploited as therapeutic targets. Recent research on the metabolic remodeling of Gln in pancreatic cancer has primarily focused on the inhibition of key enzymes, the impact on chemotherapy resistance, and the application of Gln antagonists. The progress in understanding Gln metabolism in pancreatic cancer offers valuable insights into potential novel therapeutic strategies.

Key words: glutamine, glutaminolysis, pancreatic cancer, cancer metabolism, combination therapy

中图分类号:

R735.9

刘柯, 戴梦华. 胰腺癌中谷氨酰胺代谢重构的研究进展[J]. 基础医学与临床, 2024, 44(11): 1613-1617.

LIU Ke, DAI Menghua. Advances in metabolic remodeling of glutamine in pancreatic cancer[J]. Basic & Clinical Medicine, 2024, 44(11): 1613-1617.

参考文献

[1] Zheng Y, Zhu L, Qin ZY, et al. Modulation of cellular metabolism by protein crotonylation regulates pancreatic cancer progression[J]. Cell Rep, 2023, 42. doi:10.1016/j.celrep.2023.112666.
[2] Zhang K, Li YJ, Peng LJ, et al. M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62[J]. Biol Direct, 2023, 18:1. doi:10.1186/s13062-023-00356-y.
[3] Liu H, Zhang H, Liu X, et al. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth[J]. Cancer Lett, 2023, 555:216040. doi:10.1016/j.canlet.2022.216040.
[4] Zhang D, Zhao L, Luo M, et al. Yap-Myc signaling induces pancreatic stellate cell activation through regulating glutaminolysis[J]. Exp Cell Res, 2022, 411:113000. doi:10.1016/j.yexcr.2021.113000.
[5] Rabe P, Liebing AD, Krumbholz P, et al. Succinate receptor 1 inhibits mitochondrial respiration in cancer cells addicted to glutamine[J]. Cancer Lett, 2022, 526:91-102. doi:10.1016/j.canlet.2021.11.024.
[6] Liu C, Deng S, Xiao Z, et al. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer[J]. Discov Oncol, 2023, 14:20. doi:10.1007/s12672-023-00628-z.
[7] Campbell S, Mesaros C, Izzo L, et al. Glutamine deprivation triggers NAGK-dependent hexosamine salvage[J]. eLife, 2021, 10:e62644. doi:10.7554/eLife.62644.
[8] Xiao Z, Deng S, Liu H, et al. Glutamine deprivation induces ferroptosis in pancreatic cancer cells[J]. Acta Biochim Biophys Sin, 2023, 55:1288-1300. doi:10.3724/abbs.2023029.
[9] Park SJ, Yoo HC, Ahn E, et al. Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer[J]. Cancer Res, 2023, 83:735-752. doi:10.1158/0008-5472.CAN-22-2045.
[10] Kim MJ, Kim HS, Kang HW, et al. SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancre-atic cancer[J]. Cells, 2023, 12:2509. doi:10.3390/cells12202509.
[11] Ganguly K, Bhatia R, Rauth S, et al. Mucin 5AC serves as the nexus for β-catenin/c-Myc interplay to promote glutamine dependency during pancreatic cancer chemoresistance[J]. Gastroenterology, 2022, 162:253-268.e13. doi:10.1053/j.gastro.2021.09.017.
[12] Dash S, Ueda T, Komuro A, et al. MYC/Glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance[J]. Mol Cancer Res MCR, 2023, 21:444-457. doi:10.1158/1541-7786.MCR-22-0554.
[13] Wang W, Pan H, Ren F, et al. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells[J]. Biosci Rep, 2022, 42:BSR20212171. doi:10.1042/BSR20212171.
[14] Akuetteh PDP, Huang H, Wu S, et al. Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5[J]. J Biochem Mol Toxicol, 2022, 36:e23192. doi:10.1002/jbt.23192.
[15] Ren P, Wu NA, Fu S, et al. miR-122-5p restrains pancreatic cancer cell growth and causes apoptosis by negatively regulating ASCT2[J]. Anticancer Res, 2023, 43:4379-4388. doi:10.21873/anticanres.16634.
[16] Kim JH, Lee J, Cho YR, et al. TFEB supports pancreatic cancer growth through the transcriptional regulation of glutaminase[J]. Cancers, 2021, 13:483. doi:10.3390/cancers13030483.
[17] Ozcan SC, Mutlu A, Altunok TH, et al. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells[J]. Biochem Biophys Res Commun, 2021, 571:118-124. doi:10.1016/j.bbrc.2021.07.070.
[18] Xu Y, Yu Z, Fu H, et al. Dual inhibitions on glucose/glutamine metabolisms for nontoxic pancreatic cancer therapy[J]. ACS Appl Mater Interfaces, 2022, 14:21836-21847. doi:10.1021/acsami.2c00111.
[19] Ma Y, Ling S, Li Y, et al. Loss of heterozygosity for KrasG12D promotes malignant phenotype of pancreatic ductal adenocarcinoma by activating HIF-2α-c-Myc-regulated glutamine metabolism[J]. Int J Mol Sci, 2022, 23:6697. doi:10.3390/ijms23126697.
[20] Kremer DM, Nelson BS, Lin L, et al. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis[J]. Nat Commun, 2021, 12:4860. doi:10.1038/s41467-021-24859-2.
[21] Hu T, Shukla SK, Vernucci E, et al. Metabolic rewiring by loss of Sirt5 promotes Kras-induced pancreatic cancer progression[J]. Gastroenterology, 2021, 161:1584-1600. doi:10.1053/j.gastro.2021.06.045.
[22] Yang Y, Zheng M, Han F, et al. Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming[J]. J Mol Med Berl Ger, 2022, 100:599-612. doi:10.1007/s00109-022-02181-8.
[23] Recouvreux MV, Grenier SF, Zhang Y, et al. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma[J]. Nat Cancer, 2024, 5:100-113. doi:10.1038/s43018-023-00649-1.
[24] Encarnación-Rosado J, Sohn ASW, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism[J]. Nat Cancer, 2024, 5:85-99. doi:10.1038/s43018-023-00647-3.
[25] Frejlachova A, Lencova R, Venhauerova A, et al. The combina-tion of immunotherapy and a glutamine metabo-lism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma[J]. Int Immunopharmacol, 2023, 118:110150. doi:10.1016/j.intimp.2023.110150.